Novartis’ blockbuster gene therapy Zolgensma has proven to be a major success story as a spinal muscular atrophy treatment, helping children who might not otherwise be able to stand or walk due to the rare condition. But last week, the journal Nature Biotechnology surfaced a new flaw in the therapy’s earliest phase of development, and … Continue reading More early data manipulation issues tied to Novartis blockbuster as Nature retracts paper